{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:08:19Z","timestamp":1774555699614,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ecl.2016.11.001","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T10:00:32Z","timestamp":1482487232000},"page":"207-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Novel Therapies for Postmenopausal Osteoporosis"],"prefix":"10.1016","volume":"46","author":[{"given":"Leonardo","family":"Bandeira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ecl.2016.11.001_bib1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J\u00a0Bone Miner Res"},{"issue":"6","key":"10.1016\/j.ecl.2016.11.001_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ecl.2016.11.001_bib3","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/jbmr.2269","article-title":"The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine","volume":"29","author":"Wright","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.ecl.2016.11.001_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/bmb\/ldw033","article-title":"Novel advances in the treatment of osteoporosis","volume":"119","author":"Chan","year":"2016","journal-title":"Br Med Bull"},{"issue":"4","key":"10.1016\/j.ecl.2016.11.001_bib5","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/GRF.0b013e3182a9ece0","article-title":"Osteoporosis: what's new and on the horizon","volume":"56","author":"Silva","year":"2013","journal-title":"Clin Obstet Gynecol"},{"issue":"32","key":"10.1016\/j.ecl.2016.11.001_bib6","doi-asserted-by":"crossref","first-page":"20551","DOI":"10.1074\/jbc.273.32.20551","article-title":"Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase","volume":"273","author":"Darnay","year":"1998","journal-title":"J\u00a0Biol Chem"},{"issue":"51","key":"10.1016\/j.ecl.2016.11.001_bib7","doi-asserted-by":"crossref","first-page":"34120","DOI":"10.1074\/jbc.273.51.34120","article-title":"The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily","volume":"273","author":"Galibert","year":"1998","journal-title":"J\u00a0Biol Chem"},{"issue":"8","key":"10.1016\/j.ecl.2016.11.001_bib8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jocd.2012.02.006","article-title":"Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study","volume":"16","author":"Bolognese","year":"2013","journal-title":"J\u00a0Clin Densitom"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jocd.2012.02.014","article-title":"Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis","volume":"16","author":"McClung","year":"2013","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.ecl.2016.11.001_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.abb.2014.06.003","article-title":"The immune system, bone and RANKL","volume":"561","author":"Guerrini","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.ecl.2016.11.001_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1196\/annals.1443.016","article-title":"RANK\/RANKL: regulators of immune responses and bone physiology","volume":"1143","author":"Leibbrandt","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"10.1016\/j.ecl.2016.11.001_bib13","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.ecl.2016.11.001_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.ecl.2016.11.001_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jbmr.2315","article-title":"Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study","volume":"30","author":"Tsai","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"9886","key":"10.1016\/j.ecl.2016.11.001_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"9999","key":"10.1016\/j.ecl.2016.11.001_bib17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ecl.2016.11.001_bib18","unstructured":"Bone H, Brandi ML, Brown JP, et\u00a0al. Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension Trial. ASBMR 2015 Annual Meeting. Seattle (WA), October 9-12, 2015."},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2016.11.001_bib20","unstructured":"Brown JP, Ferrari S, Gilchrist N, et\u00a0al. Discontinuation of denosumab and associated fracture incidence: analysis from FREEDOM and its Extension. ASBMR 2016 Annual Meeting. Atlanta (GA), September 16-19, 2016."},{"issue":"4","key":"10.1016\/j.ecl.2016.11.001_bib21","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.ecl.2016.11.001_bib22","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.ecl.2016.11.001_bib23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrrheum.2011.77","article-title":"Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis","volume":"7","author":"Costa","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.ecl.2016.11.001_bib24","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0002-9440(10)63068-4","article-title":"Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation","volume":"159","author":"Hou","year":"2001","journal-title":"Am J Pathol"},{"issue":"5279","key":"10.1016\/j.ecl.2016.11.001_bib25","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","article-title":"Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency","volume":"273","author":"Gelb","year":"1996","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ecl.2016.11.001_bib26","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","article-title":"Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density","volume":"25","author":"Bone","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect","volume":"26","author":"Eisman","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.ecl.2016.11.001_bib28","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.1695","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study","volume":"27","author":"Langdahl","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib29","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1210\/jc.2012-2972","article-title":"Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial","volume":"98","author":"Brixen","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2016.11.001_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jbmr.2292","article-title":"Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial","volume":"30","author":"Engelke","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00198-014-2944-6","article-title":"Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the long-term odanacatib fracture trial","volume":"26","author":"Bone","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2016.11.001_bib32","unstructured":"McClung M, Langdahl B, Papapoulos S, et\u00a0al. Odanacatib efficacy and safety in\u00a0postmenopausal women with osteoporosis: 5-year data from the extension of the phase 3 long-term odanacatib fracture trial (LOFT). ASBMR 2016 Annual Meeting. Atlanta (GA), September 16-19, 2016."},{"key":"10.1016\/j.ecl.2016.11.001_bib33","unstructured":"Papapoulos S, McClung M, Langdahl B, et\u00a0al. Safety of odanacatib in postmenopausal women with osteoporosis: 5-year data from the extension of the phase 3 long-term odanacatib fracture trial (LOFT). ASBMR 2016 Annual Meeting. Atlanta (GA), September 16-19, 2016."},{"key":"10.1016\/j.ecl.2016.11.001_bib34","unstructured":"O'Donoghue M, Cavallari I, Bonaca M, et\u00a0al. The long-term odanacatib fracture trial (LOFT): cardiovascular safety results. ASBMR Annual Meeting 2016. Atlanta (GA), September 16-19, 2016."},{"issue":"10","key":"10.1016\/j.ecl.2016.11.001_bib35","first-page":"669","article-title":"Merck &Co. drops osteoporosis drug odanacatib","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ecl.2016.11.001_bib36","unstructured":"Merck. Merck Provides Update on Odanacatib Development Program. 2016. Available at: http:\/\/www.mercknewsroom.com\/news-release\/research-and-development-news\/merck-provides-update-odanacatib-development-program. Accessed November 1, 2016."},{"key":"10.1016\/j.ecl.2016.11.001_bib37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bone.2015.07.016","article-title":"An oral cathepsin K inhibitor ONO-5334 inhibits N-terminal and C-terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women","volume":"81","author":"Tanaka","year":"2015","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.ecl.2016.11.001_bib38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00774-013-0558-2","article-title":"Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women","volume":"33","author":"Nagase","year":"2015","journal-title":"J\u00a0Bone Miner Metab"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib39","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jbmr.2047","article-title":"Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study","volume":"29","author":"Eastell","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.ecl.2016.11.001_bib40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/jbmr.2080","article-title":"The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study","volume":"29","author":"Engelke","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.ecl.2016.11.001_bib41","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1210\/endo.138.11.5505","article-title":"The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats","volume":"138","author":"Dobnig","year":"1997","journal-title":"Endocrinology"},{"issue":"19","key":"10.1016\/j.ecl.2016.11.001_bib42","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2016.11.001_bib43","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","article-title":"The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years","volume":"27","author":"Andrews","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"6","key":"10.1016\/j.ecl.2016.11.001_bib44","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jclinepi.2015.01.025","article-title":"Acting on black box warnings requires a GRADE evidence table and an implementation guide: the case of teriparatide","volume":"68","author":"Elraiyah","year":"2015","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.ecl.2016.11.001_bib45","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.1800","article-title":"Safety of osteoanabolic therapy: a decade of experience","volume":"27","author":"Cipriani","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"17","key":"10.1016\/j.ecl.2016.11.001_bib46","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2165\/00003495-200565170-00005","article-title":"Parathyroid hormone as an anabolic skeletal therapy","volume":"65","author":"Rubin","year":"2005","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ecl.2016.11.001_bib47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11914-008-0005-9","article-title":"Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window","volume":"6","author":"Bilezikian","year":"2008","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib48","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/jc.2002-021122","article-title":"Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis","volume":"88","author":"Horwitz","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2016.11.001_bib49","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1359\/jbmr.2000.15.8.1517","volume":"15","author":"Stewart","year":"2000","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.ecl.2016.11.001_bib50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S8756-3282(96)00221-9","article-title":"PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis","volume":"19","author":"Stewart","year":"1996","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.ecl.2016.11.001_bib51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.ecl.2016.11.001_bib52","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ecl.2016.11.001_bib53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11914-011-0089-5","article-title":"Sclerostin: therapeutic horizons based upon its actions","volume":"10","author":"Costa","year":"2012","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.ecl.2016.11.001_bib55","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1128\/MCB.05980-11","article-title":"Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin","volume":"31","author":"Wei","year":"2011","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","article-title":"Sclerostin: current knowledge and future perspectives","volume":"87","author":"Moester","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.1016\/j.ecl.2016.11.001_bib57","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/WNL.33.3.267","article-title":"Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship","volume":"33","author":"Stein","year":"1983","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/00016925509170789","article-title":"An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris","volume":"44","author":"Van Buchem","year":"1955","journal-title":"Acta Radiol"},{"issue":"12","key":"10.1016\/j.ecl.2016.11.001_bib59","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1210\/jc.2005-1235","article-title":"Bone mineral density in sclerosteosis; affected individuals and gene carriers","volume":"90","author":"Gardner","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ecl.2016.11.001_bib60","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1210\/jc.2003-030201","article-title":"Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal","volume":"88","author":"Wergedal","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2016.11.001_bib61","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00228-014-1735-5","article-title":"Biological agents in management of osteoporosis","volume":"70","author":"Tella","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ecl.2016.11.001_bib62","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.ecl.2016.11.001_bib63","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ecl.2016.11.001_bib64","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-016-3534-6","article-title":"Teriparatide for osteoporosis: importance of the full course","volume":"27","author":"Lindsay","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2016.11.001_bib65","first-page":"1","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","author":"Genant","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"issue":"16","key":"10.1016\/j.ecl.2016.11.001_bib66","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib67","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ecl.2016.11.001_bib68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2016.11.001_bib69","series-title":"Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy: results of the phase 3 open-label structure study","author":"Langdahl","year":"2016"},{"issue":"2","key":"10.1016\/j.ecl.2016.11.001_bib70","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A\u00a0randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"9","key":"10.1016\/j.ecl.2016.11.001_bib71","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.2489","article-title":"The Effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density","volume":"30","author":"Recknor","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.ecl.2016.11.001_bib72","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2016.11.001_bib73","unstructured":"Lilly Clinical Development Pipeline 2016. 2016. Available at: https:\/\/www.lilly.com\/_Assets\/SiteCollectionDocuments\/Pipeline\/Clinical-Development-Pipeline\/index.html#PhaseI. Accessed November 3, 2016."},{"key":"10.1016\/j.ecl.2016.11.001_bib74","unstructured":"Lilly hopes new drug delivery R&D center will prove useful in osteoporosis, diabetes arenas. 2015. Available at: http:\/\/www.fiercepharma.com\/drug-delivery\/lilly-hopes-new-drug-delivery-r-d-center-will-prove-useful-osteoporosis-diabetes. Accessed November 3, 2016."}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852916301232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852916301232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:41:05Z","timestamp":1760175665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852916301232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0889852916301232"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2016.11.001","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapies for Postmenopausal Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}